Ventilator statergy in treatment of ards for md exam answer 10 marks for easy writing
Reading File
Finding Sources
Finding Sources
Searching PubMed
"ARDS" AND "mechanical ventilation" AND "lung protective"
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, authoritative content to write a detailed 10-mark MD exam answer. Let me compose the complete response.
Ventilator Strategy in Treatment of ARDS
(10 Marks - MD Exam Answer)
Introduction
Acute Respiratory Distress Syndrome (ARDS) is characterized by diffuse alveolar damage, non-cardiogenic pulmonary edema, severe hypoxemia (PaO2/FiO2 <300), and bilateral infiltrates. The cornerstone of management is lung-protective mechanical ventilation (LPV) - a strategy designed to support gas exchange while minimizing ventilator-induced lung injury (VILI).
I. Pathophysiologic Basis for Ventilator Strategy
In ARDS, the lung is not uniformly diseased. CT imaging reveals that consolidation and atelectasis are heterogeneous - only a fraction of alveoli remain aerated (the "baby lung"). Traditional large tidal volumes, meant for a normal-sized lung, cause:
| Injury Type | Mechanism |
|---|---|
| Volutrauma | Overdistension of aerated alveoli with large tidal volumes |
| Barotrauma | Injury from excessive plateau pressure (>30 cm H2O) |
| Atelectrauma | Repetitive collapse and re-opening of alveoli |
| Biotrauma | Systemic release of proinflammatory cytokines causing multiorgan failure |
The collective term for all these is Ventilator-Induced Lung Injury (VILI).
II. Core Strategy: ARDSNet Low Tidal Volume Protocol (ARMA Trial)
The landmark ARDSNet ARMA trial (N Engl J Med 2000) randomized 861 patients. Results:
- Low TV (6 mL/kg predicted body weight [PBW]) vs. traditional TV (12 mL/kg PBW)
- Mortality reduced from 39.8% to 31.0% (p = 0.007)
- More ventilator-free days in survivors
This remains the only ventilator intervention proven to reduce mortality in ARDS.
Practical ARDSNet Protocol Steps:
Step 1 - Calculate Predicted Body Weight (PBW):
- Males: 50 + 2.3 × (height in inches - 60)
- Females: 45.5 + 2.3 × (height in inches - 60)
Step 2 - Ventilator Mode: Assist-Control (Volume Control) mode
Step 3 - Set Initial Tidal Volume: Start at 8 mL/kg PBW if baseline TV >8 mL/kg, then reduce by 1 mL/kg every 1-2 hours to target 6 mL/kg PBW
Step 4 - Plateau Pressure (Pplat) Goal: Keep Pplat ≤ 30 cm H2O
- If Pplat exceeds 30, reduce TV to as low as 4 mL/kg PBW
Step 5 - Set Respiratory Rate: Up to 35 breaths/min to maintain adequate minute ventilation
Step 6 - Oxygenation Goal: SpO2 88-95% or PaO2 55-80 mmHg (permissive hypoxemia acceptable)
III. PEEP (Positive End-Expiratory Pressure) Strategy
PEEP is essential in ARDS. It:
- Recruits collapsed alveoli, increasing functional residual capacity (FRC)
- Reduces physiologic shunt
- Prevents atelectrauma by keeping alveoli open at end-expiration
- Allows reduction of toxic FiO2 levels
ARDSNet FiO2/PEEP Table (Low PEEP strategy):
| FiO2 | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 |
|---|---|---|---|---|---|---|---|---|
| PEEP | 5 | 5-8 | 8-10 | 10 | 10-14 | 14 | 14-18 | 18-24 |
High PEEP strategy (from LOV trial and ALVEOLI trial): Consider in severe ARDS (PaO2/FiO2 <150); titrate PEEP above the lower inflection point (LIP) on the pressure-volume curve.
Key concept: On the P-V curve, PEEP should be set above the LIP (~14 cm H2O) to prevent repetitive alveolar collapse; TV should end below the upper inflection point (UIP, ~35 cm H2O) to avoid overdistension.
IV. Permissive Hypercapnia
With low TV strategy, CO2 may accumulate (hypercapnia). This is deliberately tolerated as long as pH remains ≥ 7.20-7.25. Rationale: the benefits of lung protection outweigh the harms of mild-moderate hypercapnia.
Management of acidosis:
- pH 7.15-7.30: increase RR (up to 35/min)
- pH <7.15: consider NaHCO3 infusion; may cautiously increase TV in 1 mL/kg steps
Contraindications to permissive hypercapnia:
- Raised intracranial pressure
- Acute cerebrovascular events (stroke, intracranial hemorrhage)
- Severe pulmonary hypertension / right ventricular failure
- Acute myocardial ischemia
- Pregnancy
- Tricyclic antidepressant overdose
V. Prone Positioning
- Reduces mortality in severe ARDS (PaO2/FiO2 <150)
- The PROSEVA trial (2013) showed 28-day mortality 16% vs 32.8% with prone positioning (≥16 hrs/day)
- Mechanism: more uniform distribution of ventilation, better V/Q matching, recruitment of dorsal atelectatic lung, reduction in VILI
- Should be applied early (within 36-48 hours of severe ARDS)
- Contraindications: unstable spine, open chest/abdomen, raised ICP, recent tracheal surgery
VI. Neuromuscular Blockade
- Cisatracurium infusion for 48 hours was initially shown to improve 90-day survival (ACURASYS trial, 2010)
- However, the larger PETAL-ROSE trial (2019) found no benefit over light sedation alone
- Current recommendation: use only if severe patient-ventilator dyssynchrony, uncontrolled hypoxemia, or high respiratory drive causing self-inflicted lung injury (P-SILI)
VII. Rescue / Salvage Therapies (Refractory Hypoxemia)
When conventional LPV fails (PaO2/FiO2 <80-100 despite optimization), consider:
| Rescue Therapy | Notes |
|---|---|
| Prone positioning | First-line rescue if not already done |
| Recruitment maneuvers | Brief sustained inflation to 40 cm H2O for 40 sec - controversial, risks barotrauma |
| Inhaled nitric oxide (iNO) | Improves oxygenation transiently; no mortality benefit |
| Inhaled prostacyclin | Alternative to iNO; similar effects |
| High-frequency oscillatory ventilation (HFOV) | Abandoned after OSCILLATE and OSCAR trials showed harm |
| Extracorporeal membrane oxygenation (ECMO) | EOLIA trial (2018): significant oxygenation benefit; used as bridge in severe ARDS at specialized centers |
| Extracorporeal CO2 removal (ECCO2R) | Allows further TV reduction to <6 mL/kg; investigational |
| Corticosteroids | Methylprednisolone: may help in non-resolving ARDS after 7 days; no survival benefit in late ARDS |
VIII. Weaning from Mechanical Ventilation
Begin weaning when:
- Underlying cause treated/improving
- PaO2/FiO2 >150-200 on PEEP ≤ 5-8 cm H2O
- FiO2 ≤ 0.4
- Hemodynamically stable, alert, cooperative
Spontaneous Breathing Trial (SBT): T-piece or pressure support (5-8 cm H2O) for 30-120 minutes. If tolerated, extubate.
IX. Summary Table: ARDSNet Ventilator Settings
| Parameter | Target |
|---|---|
| Mode | Assist-Control Volume Control |
| Tidal Volume | 6 mL/kg PBW (range 4-8) |
| Plateau Pressure | ≤ 30 cm H2O |
| Respiratory Rate | Up to 35/min |
| PEEP | Titrated per FiO2/PEEP table |
| FiO2 | Minimum to achieve SpO2 88-95% |
| SpO2 target | 88-95% |
| PaO2 target | 55-80 mmHg |
| pH tolerance | ≥ 7.20 (permissive hypercapnia) |
| I:E ratio | 1:1 to 1:3 (avoid inverse ratio unless salvage) |
X. Key Clinical Points for Exam
- Low TV + low Pplat = lung-protective = mortality benefit (ARMA trial: NNT ~11)
- PEEP prevents atelectrauma; keep above LIP on P-V curve
- Prone positioning for ≥16 hrs/day reduces mortality in severe ARDS (PROSEVA)
- Permissive hypercapnia is acceptable; do not use large TV to normalize CO2
- HFOV is no longer recommended (harmful in OSCILLATE trial)
- ECMO is a last resort for refractory cases at specialized centers
- Volume-control AC mode is preferred - PCV is an alternative but TV must be monitored carefully as it varies with compliance
- Use PBW (predicted body weight), not actual body weight, to calculate TV
References:
- Fishman's Pulmonary Diseases and Disorders, 5e (Chapter 141) - ARDSNet Protocol details
- Harrison's Principles of Internal Medicine 22e (Chapter 313) - Mechanical ventilation in ARDS
- Murray & Nadel's Respiratory Medicine (Lung-Protective Ventilator Strategies section)
- ARMA Trial: ARDS Network, N Engl J Med 342:1301, 2000
- PROSEVA Trial: Guerin et al., N Engl J Med 368:2159, 2013
This is a shared conversation. Sign in to Orris to start your own chat.